Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) (outSMART-LC)

[Jaybee00]

Post copied from the LC in the media thread

 

[RedFox]

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) (outSMART-LC)
https://clinicaltrials.gov/ct2/show/NCT05877508

Summary: This company, Aerium Therapeutics, is trying antibody against the coronavirus in long Covid. It's double-blind with an expected enrollment of 30, with about 20 getting the medicine and 10 the placebo. They're giving the antibodies as a one-time dose, using the PROMIS questionnaire of general health as the primary outcome, and the COMPASS autonomic questionnaire and 6-minute walk test as secondary.

 

[CRG]

Aerium Therapeutics has only been in existence since 2022 - no track record, although the scientific pedigree seems sound: https://www.aeriumtx.com/ however it's not clear why the Monoclonal Antibodies route would be useful post COVID19 when it's not recommended as a preventative: Anti-SARS-CoV-2 Monoclonal Antibodies

 

[forestglip]

Aerium Therapeutics has only been in existence since 2022 - no track record, although the scientific pedigree seems sound: https://www.aeriumtx.com/ however it's not clear why the Monoclonal Antibodies route would be useful post COVID19 when it's not recommended as a preventative: Anti-SARS-CoV-2 Monoclonal Antibodies

The linked NIH page seems to say that monoclonal antibodies work on earlier strains, and they're not recommended because they're not as effective against later strains.

Monoclonal antibodies (mAbs) that target the SARS-CoV-2 spike protein have been shown to have clinical benefits in treating SARS-CoV-2 infection. However, laboratory studies have found that the activity of anti-SARS-CoV-2 mAbs against specific variants and subvariants can vary dramatically. The anti-SARS-CoV-2 mAb products that have received Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA) are not expected to be effective against the currently circulating SARS-CoV-2 variants and subvariants. As a result, these products are not currently recommended by the COVID-19 Treatment Guidelines Panel (the Panel) for the treatment or prevention of COVID-19.

Michael Peluso says as much in the NIH Research Roadmap webinar:

"We're taking 30 people with long COVID attributed to a variant that the monoclonal would be thought to work against - so before September of [2022]."